Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOLERANCE elderly advanced soft tissue sarcoma quality-of-life study
2021-000125-27Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, cyclophosphamide and prednisolone in soft tissue sarcoma (STS) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Started Nov 2021; status: terminated.
02
Drugs
doxorubicincyclophosphamideprednisolone
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2021-000125-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000125-27.